Teacher Retirement System of Texas Has $1.24 Million Position in Elanco Animal Health Incorporated (NYSE:ELAN)

Teacher Retirement System of Texas lessened its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 29.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 102,742 shares of the company’s stock after selling 42,646 shares during the quarter. Teacher Retirement System of Texas’ holdings in Elanco Animal Health were worth $1,244,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Steward Partners Investment Advisory LLC lifted its position in Elanco Animal Health by 28.3% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 10,264 shares of the company’s stock worth $124,000 after acquiring an additional 2,264 shares during the last quarter. DDD Partners LLC acquired a new stake in Elanco Animal Health during the 4th quarter worth approximately $5,974,000. Geode Capital Management LLC boosted its stake in Elanco Animal Health by 0.8% in the 3rd quarter. Geode Capital Management LLC now owns 7,868,675 shares of the company’s stock valued at $115,623,000 after purchasing an additional 65,303 shares during the period. Atom Investors LP grew its holdings in Elanco Animal Health by 310.3% in the 3rd quarter. Atom Investors LP now owns 345,855 shares of the company’s stock valued at $5,081,000 after buying an additional 261,559 shares in the last quarter. Finally, Harbor Capital Advisors Inc. increased its position in Elanco Animal Health by 24.0% during the 4th quarter. Harbor Capital Advisors Inc. now owns 1,084,629 shares of the company’s stock worth $13,135,000 after buying an additional 209,734 shares during the period. Institutional investors own 97.48% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on ELAN shares. UBS Group reduced their target price on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Wednesday, February 26th. Leerink Partnrs upgraded shares of Elanco Animal Health to a “hold” rating in a research report on Monday, December 2nd. Stifel Nicolaus dropped their price target on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Friday, February 21st. Leerink Partners began coverage on Elanco Animal Health in a research report on Monday, December 2nd. They set a “market perform” rating and a $14.00 price target on the stock. Finally, Barclays dropped their price objective on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, Elanco Animal Health has a consensus rating of “Hold” and an average price target of $15.17.

Insider Transactions at Elanco Animal Health

In related news, Director Lawrence Erik Kurzius purchased 10,000 shares of the stock in a transaction dated Friday, March 7th. The stock was bought at an average cost of $10.90 per share, for a total transaction of $109,000.00. Following the completion of the acquisition, the director now owns 101,459 shares of the company’s stock, valued at approximately $1,105,903.10. This represents a 10.93 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.57% of the company’s stock.

Elanco Animal Health Stock Performance

Shares of NYSE:ELAN opened at $10.40 on Friday. Elanco Animal Health Incorporated has a 1 year low of $10.03 and a 1 year high of $18.80. The stock has a market capitalization of $5.14 billion, a price-to-earnings ratio of 25.99, a price-to-earnings-growth ratio of 2.50 and a beta of 1.44. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The company’s 50 day simple moving average is $11.23 and its 200 day simple moving average is $12.45.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same period last year, the firm posted $0.08 EPS. Elanco Animal Health’s quarterly revenue was down 1.4% on a year-over-year basis. As a group, research analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.